Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on September 1, 2015. The report discloses the appointment of a new senior executive and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $150,000 annually, increasing to $200,000 upon the closing of a specified additional financing.
- Annual Bonus: Target amount of up to 30% of the Base Salary, contingent on performance targets.
- Equity Grant: Options to purchase 338,888 shares of common stock at fair market value.
Material Changes
The primary material change is the appointment of Raphael J. Mannino as Senior Vice President and Chief Technology Officer, effective September 1, 2015. Dr. Mannino previously served as an Associate Professor at Rutgers University and held executive roles at BioDelivery Sciences, Inc.
Outlook, Risks, and Unusual Items
Management Commentary and Compensation Structure:
- Termination Provisions: In the event of termination without cause or for good reason, Dr. Mannino is entitled to nine months of base salary continuation and six months of accelerated option vesting.
- Change in Control: If termination occurs within 24 months of a change in control, severance increases to 18 months of base salary with full acceleration of option vesting.
- Definitions: The agreement defines "cause" to include fraud, felony conviction, or willful misconduct, and "good reason" to include material breaches of the agreement, salary reductions, or diminution of authority.
Risks: The increase in base salary is contingent on the company securing additional financing, indicating a dependency on capital markets for full compensation execution.
Investor Verification Checklist
- Verify the status of the "additional financing" required to trigger the $200,000 base salary increase.
- Review the specific performance targets established by the Board for the annual bonus calculation.
- Confirm the grant date and exercise price of the 338,888 stock options in subsequent filings.
- Assess the impact of the new CTO's background on the company's technology pipeline and R&D strategy.